Search
Human immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.
Products: Gammagard S/d, Gamastan S/dFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia. … Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalCalpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnThe drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.
Brodimoprim
go.drugbank.com/drugs/DB13795ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCarumonam
go.drugbank.com/drugs/DB13553ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Aplaviroc
go.drugbank.com/drugs/DB06497InvestigationalA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
Bifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.